DesignMedix

About:

DesignMedix develops pharmaceutical drugs designed to address the rapid rise in drug resistance in multiple diseases.

Top Investors: Oregon Venture Fund, National Institutes of Health, Portland Seed Fund, Keiretsu Forum, Willamette University

Description:

DesignMedix develops pharmaceutical drugs designed to address the rapid rise in drug resistance in multiple diseases. Its drugs are developed by covalently linking a chemical moiety derived from a resistance reversal agent in order to fulfill the roles of both therapeutic agent and resistance reversal agent, enabling medical practitioners to treat malaria and other infectious diseases without a hassle.

Total Funding Amount:

$8.35M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Portland, Oregon, United States

Founded Date:

2006-01-01

Contact Email:

info(AT)designmedix.com

Founders:

Sandra Shotwell

Number of Employees:

1-10

Last Funding Date:

2017-04-12

IPO Status:

Private

Industries: